These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
390 related articles for article (PubMed ID: 38632474)
1. Targeting the incretin system in obesity and type 2 diabetes mellitus. Ansari S; Khoo B; Tan T Nat Rev Endocrinol; 2024 Aug; 20(8):447-459. PubMed ID: 38632474 [TBL] [Abstract][Full Text] [Related]
2. Glucagon-like peptide 1 in health and disease. Andersen A; Lund A; Knop FK; Vilsbøll T Nat Rev Endocrinol; 2018 Jul; 14(7):390-403. PubMed ID: 29728598 [TBL] [Abstract][Full Text] [Related]
3. Therapies for inter-relating diabetes and obesity - GLP-1 and obesity. Iepsen EW; Torekov SS; Holst JJ Expert Opin Pharmacother; 2014 Dec; 15(17):2487-500. PubMed ID: 25260877 [TBL] [Abstract][Full Text] [Related]
4. The dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist tirzepatide: a novel cardiometabolic therapeutic prospect. Fisman EZ; Tenenbaum A Cardiovasc Diabetol; 2021 Nov; 20(1):225. PubMed ID: 34819089 [TBL] [Abstract][Full Text] [Related]
5. Diabetes and obesity treatment based on dual incretin receptor activation: 'twincretins'. Skow MA; Bergmann NC; Knop FK Diabetes Obes Metab; 2016 Sep; 18(9):847-54. PubMed ID: 27160961 [TBL] [Abstract][Full Text] [Related]
6. Focus on incretin-based therapies: targeting the core defects of type 2 diabetes. Jellinger PS Postgrad Med; 2011 Jan; 123(1):53-65. PubMed ID: 21293084 [TBL] [Abstract][Full Text] [Related]
7. Clarifying the role of incretin-based therapies in the treatment of type 2 diabetes mellitus. Campbell RK Clin Ther; 2011 May; 33(5):511-27. PubMed ID: 21665040 [TBL] [Abstract][Full Text] [Related]
8. Incretin-based therapy of type 2 diabetes mellitus. Knop FK; Vilsbøll T; Holst JJ Curr Protein Pept Sci; 2009 Feb; 10(1):46-55. PubMed ID: 19275672 [TBL] [Abstract][Full Text] [Related]
9. Recent advances in peptide-based therapies for obesity and type 2 diabetes. Bailey CJ; Flatt PR; Conlon JM Peptides; 2024 Mar; 173():171149. PubMed ID: 38184193 [TBL] [Abstract][Full Text] [Related]
10. Recent Advances in Incretin-Based Pharmacotherapies for the Treatment of Obesity and Diabetes. Tan Q; Akindehin SE; Orsso CE; Waldner RC; DiMarchi RD; Müller TD; Haqq AM Front Endocrinol (Lausanne); 2022; 13():838410. PubMed ID: 35299971 [TBL] [Abstract][Full Text] [Related]
11. Revisiting the concept of incretin and enteroendocrine L-cells as type 2 diabetes mellitus treatment. Lok KH; Wareham NJ; Nair RS; How CW; Chuah LH Pharmacol Res; 2022 Jun; 180():106237. PubMed ID: 35487405 [TBL] [Abstract][Full Text] [Related]
12. Glucagon-like Peptide-1 Receptor Agonists in the Management of Type 2 Diabetes Mellitus and Obesity: The Impact of Pharmacological Properties and Genetic Factors. Klen J; Dolžan V Int J Mol Sci; 2022 Mar; 23(7):. PubMed ID: 35408810 [TBL] [Abstract][Full Text] [Related]
13. Differentiating among incretin therapies: a multiple-target approach to type 2 diabetes. Cornell S J Clin Pharm Ther; 2012 Oct; 37(5):510-24. PubMed ID: 22436069 [TBL] [Abstract][Full Text] [Related]
14. The future of incretins in the treatment of obesity and non-alcoholic fatty liver disease. Andreasen CR; Andersen A; Vilsbøll T Diabetologia; 2023 Oct; 66(10):1846-1858. PubMed ID: 37498367 [TBL] [Abstract][Full Text] [Related]
16. Physiology of incretins and loss of incretin effect in type 2 diabetes and obesity. Opinto G; Natalicchio A; Marchetti P Arch Physiol Biochem; 2013 Oct; 119(4):170-8. PubMed ID: 23859800 [TBL] [Abstract][Full Text] [Related]
17. Incretin actions and consequences of incretin-based therapies: lessons from complementary animal models. Renner S; Blutke A; Streckel E; Wanke R; Wolf E J Pathol; 2016 Jan; 238(2):345-58. PubMed ID: 26455904 [TBL] [Abstract][Full Text] [Related]
18. Incretins: their physiology and application in the treatment of diabetes mellitus. Tasyurek HM; Altunbas HA; Balci MK; Sanlioglu S Diabetes Metab Res Rev; 2014 Jul; 30(5):354-71. PubMed ID: 24989141 [TBL] [Abstract][Full Text] [Related]
19. Glucagon-Like Peptide-1 Receptor Agonists and Dual Glucose-Dependent Insulinotropic Polypeptide/Glucagon-Like Peptide-1 Receptor Agonists in the Treatment of Obesity/Metabolic Syndrome, Prediabetes/Diabetes and Non-Alcoholic Fatty Liver Disease-Current Evidence. Muzurović EM; Volčanšek Š; Tomšić KZ; Janež A; Mikhailidis DP; Rizzo M; Mantzoros CS J Cardiovasc Pharmacol Ther; 2022; 27():10742484221146371. PubMed ID: 36546652 [TBL] [Abstract][Full Text] [Related]
20. The incretin/glucagon system as a target for pharmacotherapy of obesity. Del Prato S; Gallwitz B; Holst JJ; Meier JJ Obes Rev; 2022 Feb; 23(2):e13372. PubMed ID: 34713962 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]